|
www.PicksThatMove.com: "Picks that move" Alerts, August 7, 2009: RDEA, NVAX, OPMR, CDCS, NEXM and CWCO.
(M2 PressWIRE Via Acquire Media NewsEdge) Picksthatmove.com Alerts include Ardea Biosciences, Inc. (Nasdaq: RDEA); Novavax, Inc. (Nasdaq: NVAX); Optimal Group Inc. (Nasdaq: OPMR); CDC Software (NASDAQ: CDCS); NexMed, Inc. (Nasdaq: NEXM) and Consolidated Water Co. Ltd. (Nasdaq: CWCO)
-- August 7, 2009 Ardea Biosciences, Inc. (Nasdaq:RDEA) trading at $20.92 on a volume of 16,439 shares.
In a press release out on August 7, 2009 Ardea Biosciences Reports Recent Accomplishments and Announces Second Quarter and Year-to-Date 2009 Financial Results
SAN DIEGO, Aug 07, 2009 -- Ardea Biosciences, Inc. (Nasdaq:RDEA), a biotechnology company focused on the development of small-molecule therapeutics for the treatment of gout, cancer, inflammatory diseases and human immunodeficiency virus (HIV), today reported recent accomplishments and financial results for the second quarter and six months ended June 30, 2009.
About Ardea Biosciences, Inc.
Ardea Biosciences, Inc., of San Diego, California, is a biotechnology company focused on the development of small-molecule therapeutics for the treatment of gout, cancer, inflammatory diseases and human immunodeficiency virus (HIV). RDEA594, our lead product candidate for the treatment of hyperuricemia and gout, is a selective URAT1 transporter inhibitor in Phase 2 clinical development. Our next-generation development candidate for the treatment of hyperuricemia and gout, RDEA684, is currently in preclinical development in preparation for Phase 1 studies in normal healthy volunteers. RDEA119, a potent and specific inhibitor of mitogen-activated ERK kinase (MEK) and our lead product candidate for the treatment of cancer, is being developed under a global license agreement with Bayer HealthCare. RDEA119 is being evaluated as a single agent in a Phase 1 study in advanced cancer patients and in a Phase 1/2 study in combination with sorafenib (Nexavar(R); Bayer HealthCare, Onyx Pharmaceuticals) in advanced cancer patients. RDEA119 has also been evaluated for potential use in inflammatory diseases in a Phase 1 study in normal healthy volunteers. RDEA806, our lead product candidate for the treatment of HIV, is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that has successfully completed a Phase 2a study in HIV patients.
-- August 7, 2009 Novavax, Inc. (Nasdaq: NVAX) trading at $4.90 on a volume of 1.16M shares
In a press release on August 7, 2009 Novavax Reports Second Quarter 2009 Financial Results
ROCKVILLE, Md., Aug 07, 2009 -- Novavax, Inc. (Nasdaq: NVAX) today reported a net loss of $8.5 million, or $0.10 per share, for the second quarter of 2009 compared to a net loss of $9.4 million, or $0.15 per share, for the second quarter of 2008.
About Novavax
Novavax, Inc. is a clinical stage biotechnology company, creating novel vaccines to address a broad range of infectious diseases worldwide using advanced proprietary virus-like particle (VLP) technology. The Company produces these VLP based, potent, recombinant vaccines utilizing new, and efficient manufacturing approaches. Additional information about Novavax is available at www.novavax.com and in the Company's various filings with the Securities and Exchange Commission.
-- August 7, 2009 Optimal Group Inc. (Nasdaq:OPMR) trading at $0.429 on a volume of 4,719 shares.
In a press release out on August 7, 2009 Optimal Group Announces Second Quarter 2009 Results
MONTREAL, Aug 7, 2009 -- Optimal Group Inc. (Nasdaq:OPMR) today announced its financial results for the second quarter ended June 30, 2009. All references are in U.S. dollars.
About Optimal Group
Optimal Group Inc. has operated and, through various subsidiaries, has actively managed a variety of businesses.
Optimal Group Inc. currently operates:
The WowWee group of companies, with operations in Hong Kong, Carlsbad, California, Brussels, Belgium and Montreal, Quebec. WowWee Group Limited, based in Hong Kong, is a leading designer, developer, marketer and distributor of technology-based consumer robotic, toy and entertainment products.
For more information about Optimal, please visit the Company's website at www.optimalgrp.com.
-- August 7, 2009 CDC Software (NASDAQ: CDCS) trading at $9.82 on a volume of 173,071 shares.
In a press release out on August 7, 2009 CDC Software to Hold Second Quarter 2009 Earnings Call on August 18, 2009 at 8:00 AM EDT
HONG KONG & ATLANTA, Aug 07, 2009 -- CDC Software (NASDAQ: CDCS) will hold a conference call to discuss the company's second quarter 2009 earnings and operating results on Tuesday, August 18, 2009, at 8:00 A.M. EDT. An earnings release will precede the call, posting to the wires after the market closes on August 17th, 2009.
About CDC Software
CDC Software (NASDAQ: CDCS) is a provider of enterprise software applications designed to help organizations deliver a superior customer experience while increasing efficiencies and profitability.
CDC Software's product suite includes: CDC Factory (manufacturing operations management), Ross ERP (enterprise resource planning) and SCM (supply chain management), CDC Supply Chain (supply chain management, warehouse management and order management), Pivotal CRM and Saratoga CRM (customer relationship management), Respond (customer complaint and feedback management), c360 CRM add-on products, industry solutions and development tools for the Microsoft Dynamics CRM platform, Platinum HRM (human resources) and business analytics solutions.
These industry-specific solutions are used by more than 6,000 customers worldwide within the manufacturing, financial services, health care, home building, real estate, wholesale and retail distribution industries. The company also offers a full portfolio of services that span the life cycle of its software applications. For more information, please visitwww.cdcsoftware.com
-- August 7, 2009 NexMed, Inc. (Nasdaq: NEXM) trading at $0.19 on a volume of 142,182 shares.
In a press release out on August 7, 2009 NexMed Announces Second Quarter 2009 Financial Results Conference Call
Conference Call/Webcast to be held Tuesday, August 11, 2009 at 10:00 a.m. EDT-
EAST WINDSOR, N.J., Aug 07, 2009 -- NexMed, Inc. (Nasdaq: NEXM), a developer of innovative topical products based on the NexACT(R) technology, today announced that management will hold a conference call to discuss 2009 second quarter financial results and ongoing corporate activities, on Tuesday, August 11, 2009 at 10:00 a.m. EDT. The Company will file its Form 10-Q by the end of business on Monday, August 10, 2009.
About NexMed
NexMed's pipeline includes a late stage terbinafine treatment for onychomycosis, a late stage alprostadil treatment for erectile dysfunction, a P 2 alprostadil treatment for female sexual arousal disorder, and an early stage treatment for psoriasis. For further information about NexMed, go to www.nexmed.com.
-- August 7, 2009 Consolidated Water Co. Ltd. (Nasdaq: CWCO) trading at $17.84 on a volume of 5,706 shares
In a press release out on August 7, 2009 Consolidated Water Co. Ltd. Schedules Second Quarter Conference Call for Monday, August 10, 2009
GEORGE TOWN, Grand Cayman, Cayman Islands, Aug 07, 2009 -- Consolidated Water Co. Ltd. (Nasdaq: CWCO), which develops and operates seawater desalination plants and water distribution systems in areas where naturally occurring supplies of potable water are scarce or nonexistent, today announced that it has scheduled a conference call for 2:00 p.m. EDT on Monday, August 10, 2009, to review the Company's operating results for the second quarter and first half of 2009, along with other relevant topics of interest.
About Consolidated Water Co. Ltd.
Consolidated Water Co. Ltd. develops and operates seawater desalination plants and water distribution systems in areas of the world where naturally occurring supplies of potable water are scarce or nonexistent. The Company operates water production and/or distribution facilities in the Cayman Islands, Belize, the British Virgin Islands, The Commonwealth of The Bahamas and Bermuda.
Consolidated Water Co. Ltd. is headquartered in George Town, Grand Cayman, in the Cayman Islands. The Company's ordinary (common) shares are traded on the NASDAQ Global Select Market under the symbol "CWCO". Additional information on the Company is available on its website at http://www.cwco.com
About PicksThatMove.com
www.picksthatmove.com team of excellence strives to find undervalued, good momentum stock plays. We provide financial and investor relations services for small to mid-cap stocks with weekly and special newsletters to keep you informed of the latest movers. Unlike other sites, we explore, research, and understand all aspects of a company. We only recommend companies we feel has the potential for future higher valuations. Our seasoned research team is always looking for the next Xtreme Pick to send to you.
www.picksthatmove.com is a leading stock website that provides free daily alerts on stocks that are moving up. www.picksthatmove.com also tracks small cap stocks that are on the brink of exploding. We also feature companies on our website with research report, analysis, and newsletters. To feature a company on our web site please contact us at Info@picksthatmove.com
www.picksthatmove.com is an independent electronic publication that provides information on selected publicly traded companies. www.picksthatmove.com is not a registered investment advisor or broker-dealer. www.picksthatmove.com affiliates, officers, directors and employees may buy and sell additional shares in any company mentioned herein and may profit in the event those shares rise in value. Please do your own Due Diligence before investing in any of the stocks mentioned above.
((Comments on this story may be sent to info@m2.com))
(c) 2009 M2 COMMUNICATIONS
[ Back To TMCnet.com's Homepage ]
|
INDUSTRIES
Activate Email 
Find Solutions for Enterprises, SMBs & Service Providers at the INTERNET TELEPHONY Conference and EXPO East, January 20-22, 2010. Miami, FL.
